Zobrazeno 1 - 10
of 97
pro vyhledávání: '"Horvat Ledinek A"'
Autor:
Emeršič, Andreja, Karikari, Thomas K., Kac, Przemysław R., Gonzalez-Ortiz, Fernando, Dulewicz, Maciej, Ashton, Nicholas J., Brecl Jakob, Gregor, Horvat Ledinek, Alenka, Hanrieder, Jörg, Zetterberg, Henrik, Rot, Uroš, Čučnik, Saša, Blennow, Kaj
Publikováno v:
In Multiple Sclerosis and Related Disorders October 2024 90
Autor:
Adamec, Ivan, Brecl Jakob, Gregor, Drulović, Jelena, Sellner, Johann, Bilić, Ervina, Sitaš, Barbara, Bilić, Hrvoje, Tamaš, Olivera, Budimkić, Maja, Veselinović, Nikola, Horvat Ledinek, Alenka, Jerše, Jana, Gomezelj, Sarah, Hauer, Larissa, Krbot Skorić, Magdalena, Habek, Mario
Publikováno v:
In Journal of the Neurological Sciences 15 December 2022 443
Publikováno v:
Journal of Neurology; Sep2024, Vol. 271 Issue 9, p6363-6367, 5p
Autor:
Thomas Berger, Monika Adamczyk-Sowa, Tünde Csépány, Franz Fazekas, Tanja Hojs Fabjan, Dana Horáková, Alenka Horvat Ledinek, Zsolt Illes, Gisela Kobelt, Saša Šega Jazbec, Eleonóra Klímová, Fritz Leutmezer, Konrad Rejdak, Csilla Rozsa, Johann Sellner, Krzysztof Selmaj, Pavel Štouracˇ, Jarmila Szilasiová, Peter Turcˇáni, Marta Vachová, Manuela Vanecková, László Vécsei, Eva Kubala Havrdová
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 13 (2020)
At two meetings of a Central European board of multiple sclerosis (MS) experts in 2018 and 2019 factors influencing daily treatment choices in MS, especially practice guidelines, biomarkers and burden of disease, were discussed. The heterogeneity of
Externí odkaz:
https://doaj.org/article/246cb9f41dbf4f6e88edc22268ad7a97
Publikováno v:
Clinical Parkinsonism & Related Disorders, Vol 3, Iss , Pp 100055- (2020)
More than 30 patients with multiple sclerosis (MS) and Parkinson's disease (PD) have been reported so far. Theories on the co-occurrence of MS and PD range from coincidental to causal. There has been only one report of MS in young onset PD in a patie
Externí odkaz:
https://doaj.org/article/6ebeab23c26c430781a76dc7863d4b93
Autor:
Magdalena Krbot Skorić, Mario Habek, Saša Šega Jazbec, Gregor Brecl Jakob, Sarah Gomezelj, Tereza Gabelić, Ivan Adamec, Alenka Horvat Ledinek, Uroš Rot, Barbara Barun
Publikováno v:
Neurological Sciences. 42:4591-4597
Objective: So far, a limited number of real-world evidence studies about the effectiveness and safety of alemtuzumab (ALM) have been published, some of them with a relatively small number of included patients. We aimed to study the efficacy and safet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e95a6b5b9ada37db337fa0ecd31f5e34
https://doi.org/10.1007/s10072-021-05145-x
https://doi.org/10.1007/s10072-021-05145-x
Autor:
Zsófia Kokas, Anett Járdánházy, Dániel Sandi, Tamás Biernacki, Zsanett Fricska-Nagy, Judit Füvesi, Halina Bartosik-Psujek, Vanja Basic Kes, Thomas Berger, Achim Berthele, Jelena Drulovic, Bernhard Hemmer, Dana Horakova, Alenka Horvat Ledinek, Eva Kubala Havrdova, Melinda Magyari, Konrad Rejdak, Cristina Tiu, Peter Turcani, Péter Klivényi, Zsigmond Tamás Kincses, László Vécsei, Krisztina Bencsik
Publikováno v:
Multiple sclerosis and related disorders. 69
In 2018 multiple sclerosis (MS) care unit (MSCU) recommendations were defined. Nevertheless, the information on MS care, and whether MS centres fulfil the international recommendation is limited. Thus our objectives were to assess whether centres mee
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b662f9f61cde51a355c6d981a12405ac
https://pubmed.ncbi.nlm.nih.gov/36413917
https://pubmed.ncbi.nlm.nih.gov/36413917
Publikováno v:
International Journal of Dermatology. 61
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23189fa0328170dea04f6f2cf72b8928
https://doi.org/10.1111/ijd.16208
https://doi.org/10.1111/ijd.16208
Publikováno v:
Rad Hrvatske akademije znanosti i umjetnosti. Medicinske znanosti
Volume 552
Issue 58-59
Volume 552
Issue 58-59
Introduction: Disease-modifying therapy (DMT) dramatically influenced the management of re- lapsing-remitting multiple sclerosis (RRMS). Novel medicines have been developing constantly and therapeutic strategy has changed. We aimed to analyse the dev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::83dcf4c79cb844bb953ccc8c20c5788a
https://hrcak.srce.hr/280797
https://hrcak.srce.hr/280797